Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KAZIA THERAPEUTICS LTDKZIA · Entity 6537 | Chief Scientific Officer | June 19, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KAZIA THERAPEUTICS LTD
Report date June 19, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.48 | Direct | 250,000 |
Reported balance
After 2026-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 250,000 · Balance 250,000 F1: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 23, 2026 22:47 UTC | KAZIA THERAPEUTICS LTD KZIA · Entity 6537 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $18.48 | $0.00 |
DisclosureSEC source: 0001213900-26-071230 · ownership.xml · derivative · entry 1 Rao Sudha · CIK 0002132027 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: ADSs · 250,000 shares Expires not disclosed F1 · shares: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.exercise_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. F1 · derivative.expiration_date: Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.